case_images: PMC10980546_01
case_images: Time course for clinical parameters, diagnosis, and treatment. Nivolumab and ipilimumab were administered at 0, 4, 7, 10, 12, 16, and 18 weeks. CPR: C-peptide reactivity; ACTH: adrenocorticotropic hormone; FT4: free thyroxine; TSH: thyroid-stimulating hormone.
case_images: CRIE2024-4662803.001.jpg
case_images: PMC10980546_01_CRIE2024-4662803.001.jpg
case_images: fig1
case_images: TSH, FT4, adrenocorticotrophic hormone (ACTH), and cortisol during the clinical course of the disease are presented in Figure 1.
case_images: (a) Diurnal variations for blood ACTH and cortisol, and urinary cortisol indicated low levels. (b) Corticotropin-releasing hormone (CRH) stimulation testing showed no change in adrenocorticotropic hormone (ACTH) or cortisol level. The CRH stimulation test was conducted in the morning under a fasting condition.
case_images: CRIE2024-4662803.002.jpg
case_images: PMC10980546_01_CRIE2024-4662803.002.jpg
case_images: fig2
case_images: ACTH/cortisol in low levels as well as in low urinary cortisol levels, while a corticotropin-releasing hormone (CRH) stimulation test demonstrated no significant response for either ACTH or cortisol level (Figure 2). A pituitary contrast-enhanced MRI (Figure 3) revealed heterogeneous enhancement of the pituitary gland, which is a characteristic finding of the ICI-induced hypophysitis.
case_images: Pituitary contrast-enhanced MRI revealed heterogeneous enhancement of the pituitary gland.
case_images: CRIE2024-4662803.003.jpg
case_images: PMC10980546_01_CRIE2024-4662803.003.jpg
case_images: fig3
case_images: ACTH/cortisol in low levels as well as in low urinary cortisol levels, while a corticotropin-releasing hormone (CRH) stimulation test demonstrated no significant response for either ACTH or cortisol level (Figure 2). A pituitary contrast-enhanced MRI (Figure 3) revealed heterogeneous enhancement of the pituitary gland, which is a characteristic finding of the ICI-induced hypophysitis.